Skip to content

The effect of mouthwashes on intra-oral halitosis (bad breath)

The effect of different commercially available mouthwashes with active ingredients in a group of systemically and periodontally healthy subjects with intra-oral halitosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN18353746
Enrollment
52
Registered
2024-09-19
Start date
2023-11-13
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intra-oral halitosis Oral Health

Interventions

This study involves a mouthwash product containing zinc acetate and chlorhexidine diacetate without alcohol compared to a negative comparison (water). There will be a positive comparison mouthwash con

Sponsors

Academic Centre for Dentistry Amsterdam (ACTA)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults =18 years of age 2. Classified as systemically healthy as assessed by a medical questionnaire; no systemic diseases 3. Periodontally healthy classified according to the periodical periodontal screening (pps) tool: pps 1 or pps 2 with not more than 2 sites with probing pocket depths of 5mm 4. Have a minimum of 20 natural teeth 5. Having finished the necessary dental treatment(s) 6. Willing to brush twice daily and interdental cleaning as usual 7. Willing to temporary stop cleaning the tongue and use of an oral irrigator (starts from the screening until the end of the clinical trial) 8. Willing not to use any other mouthwash than the provided mouthwash of this clinical trial (starts at least two weeks before the first visit or from screening until the end of the clinical trial) 9. Willing to temporary stop using chewing gum (starts at least two weeks before the first visit or from screening until the end of the clinical trial) 10. Willing to keep calendar on use of mouthwash 11. Willing to give their mobile phone number in order to send the participant a text message to remind them of their appointments and instructions 12. Has visit their dentist on regular basis in the past 6 months – 12 months 13. Minimal scores for intra-oral halitosis assessment at screening; 13.1. Hydrogen sulfide >112 ppb as measured by OralChroma (Erovic Ademovski et al. 2017) 13.2. Total volatile sulfur compound level >160 ppb as determined with a halimeter (Erovic Ademovski et al. 2017) and 13.3. Oral organoleptic score =2 (Rosenberg & Mcculloch 1992) 14. Self-reported halitosis

Exclusion criteria

Exclusion criteria: 1. Allergy or hypersensitive to any of the ingredients of the products; zinc acetate, chlorhexidine diacetate, cetylpyridinium chloride, essential-oils, fluoride 2. Pps 2 with > 2 sites with a probing pocket dept of 5mm 3. Pps 3 4. Open carious lesions 5. Dental students or dental care professionals 6. Self-reported pregnancy and/or lactating 7. Systemic medication related to oral dryness 8. Systemic antibiotic therapy within the preceding 3 months 9. Smoking or quitted smoking <1 year before the screening appointment 10. Extra-oral halitosis (Tangerman & Winkel 2008) 11. Night guard 12. Orthodontic brackets (retainer is allowed) 13. Removable prosthesis 14. Oral piercings

Design outcomes

Primary

MeasureTime frame
Volatile sulphur compound hydrogen sulfide level (in ppb) assessed with the OralChroma at baseline, day 7 and 21

Secondary

MeasureTime frame
Measured at baseline, day 7 and 21 unless noted otherwise: 1. Methyl mercaptan levels will be assessed by OralChroma 2. Total oral sulfide concentration will be measured with the Halimeter device and breath odor intensity with organoleptic scores 3. Winkel tongue coating index and the Gomez tongue index will be used to assess the tongue coating assessed 4. “Odostomia” questionnaire scores (subject’s perception of his/her own breath odor) will be filled out at at baseline and day 21. As well as subjects’ attitudes towards the mouthwashes used at day 21

Countries

Netherlands

Contacts

Public ContactEveline van der Sluijs
e.vd.sluijs@acta.nl+31 20 59 80176

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026